Research Topics
| E GaneSummaryAffiliation: University of Auckland Country: New Zealand Publications
| Collaborators
|
Detail Information
Publications
Management of chronic viral hepatitis before and after renal transplantationEdward Gane
New Zealand Liver Transplant Unit, Auckland Hospital, New Zealand
Transplantation 74:427-37. 2002..Established cirrhosis with active viral infection should be considered a relative contraindication to isolated renal transplantation...
A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxisPeter W Angus
Victorian Liver Transplant Unit, Austin Health, Victoria, Australia
Hepatology 48:1460-6. 2008..CONCLUSION: Compared with combination HBIG plus lamivudine prophylaxis, combination adefovir plus lamivudine provides equivalent protection against recurrent HBV infection but with better tolerability and less cost...- Liver transplantation in New Zealand: the first four yearsEd Gane
New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, New Zealand
N Z Med J 115:U120. 2002..To summarise the transplant-related activity of the New Zealand Liver Transplant Unit over the first four years... - Treatment of recurrent hepatitis CEd Gane
New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, NZ
Liver Transpl 8:S28-37. 2002..9. In a recent study, posttransplant immunoprophylaxis with polyclonal hepatitis C immunoglobulin had no effect on recurrent viremia or hepatitis... - The natural history and outcome of liver transplantation in hepatitis C virus-infected recipientsEdward Gane
New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, New Zealand
Liver Transpl 9:S28-34. 2003..The 3-year survival is <10% after the onset of hepatitis C virus-related allograft failure, compared with 60% after decompensation in immunocompetent patients... - Treatment of chronic hepatitis C in patients with renal diseaseEdward Gane
New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, New Zealand
Med J Malaysia 60:72-6. 2005 - Liver transplantation in chronic hepatitis BEdward Gane
New Zealand Liver Transplant Unit, Auckland Hospital, Auckland, New Zealand
Med J Malaysia 60:88-9. 2005 - Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis CDaniele Prati
Ospedale A Manzoni, Lecco and IRCCS Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy
J Hepatol 44:679-85. 2006..To clarify the role and interactions of viral and host factors in inducing liver cell injury, we examined the associations of several virological and metabolic variables with serum alanine aminotransferase levels... - Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of lifeSanjeev Arora
Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131 0001, USA
J Gastroenterol Hepatol 21:406-12. 2006..HRQoL in the present population was also compared with HRQoL in patients with elevated ALT levels, observed in a previous study... - Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudinePierre Vandepapeliere
GlaxoSmithKline Biologicals, 1330 Rixensart, Belgium
Vaccine 25:8585-97. 2007.... - Telbivudine versus lamivudine in patients with chronic hepatitis BChing Lung Lai
University Department of Medicine, Queen Mary Hospital, Hong Kong, China
N Engl J Med 357:2576-88. 2007..Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B... - Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis BGeorge K K Lau
Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
N Engl J Med 352:2682-95. 2005.... - Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 updateYun Fan Liaw
Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan
Liver Int 25:472-89. 2005..A large amount of new data on the treatment of chronic hepatitis B has become available such that the 2003 consensus statement requires revision and update... - Screening for chronic hepatitis B infection in New Zealand: unfinished businessEdward Gane
N Z Med J 118:U1344. 2005 - Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levelsStefan Zeuzem
Saarland University Hospital, Homburg Saar, Germany
Gastroenterology 127:1724-32. 2004.... - Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis CJens Rasenack
Klinikum der Albert Ludwigs Universität, Freiburg, Germany
Pharmacoeconomics 21:341-9. 2003..Treatment with peginterferon alpha-2a (40kD) provides an improved sustained response over unmodified interferon alpha-2a... - Sorafenib in advanced hepatocellular carcinomaJosep M Llovet
Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
N Engl J Med 359:378-90. 2008..A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma... - Patient and graft survival after liver transplantation for hereditary hemochromatosis: Implications for pathogenesisDarrell H G Crawford
Queensland Liver Transplant Service and The University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
Hepatology 39:1655-62. 2004..Our data suggest that iron excess in HH does not wholly depend on intestinal iron absorption but is also influenced by liver factors that moderate iron metabolism... - Liver transplantation in Jehovah's Witness patients in AustralasiaGary P Jeffrey
Western Australian Liver Transplantation Service, Sir Charles Gairdner Hospital, Perth, WA, Australia
Med J Aust 187:188-9. 2007..To our knowledge, these are the first such cases in Australasia. The techniques used to minimise blood loss and transfusion requirements could potentially benefit all patients undergoing major surgery... - Polymorphism in intron 1 of the interferon-gamma gene influences both serum immunoglobulin E levels and the risk for chronic hepatitis B virus infection in PolynesiansWilliam Abbott
New Zealand Liver Transplant Unit, Auckland City Hospital, Private Bag 92 024, Auckland, New Zealand
Immunogenetics 59:187-95. 2007..These findings are consistent with a previous report of an association between +875 IFNGCA and [tsIgE] and provide preliminary evidence of a new association with the outcome of an HBV infection... - Practical difficulties in the management of hepatitis B in the Asia-Pacific regionRosmawati Mohamed
Department of Medicine, University Malaya, Kuala Lumpur, Malaysia
J Gastroenterol Hepatol 19:958-69. 2004.... - Resolution of alcoholic neuropathy following liver transplantationEdward Gane
New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand
Liver Transpl 10:1545-8. 2004..In conclusion, this case suggests that peripheral neuropathy in a patient with alcoholic cirrhosis may resolve following liver transplantation and should not constitute a contraindication to transplantation, even when it is disabling... - Liver transplantation for hepatocellular carcinoma in New Zealand: a prospective intent-to-treat analysisYuhji Marui
New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand
N Z Med J 118:U1532. 2005..Based on this experience strategies aimed at preventing waiting list drop out have been adopted, however expansion of tumour-related selection criteria cannot be recommended without a concomitant increase in donor organ availability...